Anuradha Aparasu, MD
Internal Medicine · Sugar Land, TXNPI 1477510014
Payments from drug & device makers
Across 379 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$707
- Boehringer Ingelheim$485
- Bayer$475
- Amgen$415
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,699100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 84 | $1,569 |
| Lilly USA, LLC | 66 | $1,102 |
| AstraZeneca | 44 | $707 |
| Boehringer Ingelheim | 30 | $485 |
| Bayer | 25 | $475 |
| Amgen(2 entities) | 24 | $415 |
| Pfizer | 17 | $321 |
| Johnson & Johnson | 16 | $314 |
| Sanofi-aventis U.S. LLC | 11 | $182 |
| Amarin Pharma, Inc. | 8 | $167 |
| GSK | 9 | $165 |
| Abbott | 7 | $132 |
| AbbVie(2 entities) | 7 | $124 |
| Novartis | 5 | $96 |
| Exact Sciences | 4 | $78 |
| Merck | 5 | $77 |
| Astellas Pharma US Inc | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Edwards Lifesciences | 1 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Boston Scientific | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Optinose US, Inc. | 1 | $18 |
| Valeritas, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$6,728 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $82,866 |
| MounjaroTirzepatide | 32 | $55,164 |
| JardianceEmpagliflozin | 68 | $54,385 |
| RybelsusSemaglutide | 34 | $46,804 |
| FarxigaDapagliflozin Propanediol | 64 | $43,719 |
| JanuviaSitagliptin Phosphate | 37 | $43,485 |
| TrulicityDulaglutide | 27 | $33,350 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $30,666 |
| EliquisApixaban | 30 | $28,877 |
| XareltoRivaroxaban | 13 | $16,635 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $16,049 |
| TradjentaLinagliptin | 19 | $15,317 |
| Spiriva RespimatTiotropium Bromide | 17 | $13,598 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $13,189 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,569 | $129,67098 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,102 | $88,51559 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $485 | $83,300104 claims |
| AstraZenecaFarxiga | $707 | $43,71964 claims |
| MerckJanuvia | $77 | $43,48537 claims |
| PfizerEliquis | $321 | $28,87730 claims |
| Johnson & JohnsonXarelto | $314 | $16,63513 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $182 | $13,18922 claims |
| GSKTrelegy Ellipta, Arexvy | $165 | $12,23926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Sugar Land
- Harish ThakkarSugar Land$6.3M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.